Dr. Beth Zamboni received a BS in Statistics from the University of Pittsburgh, MS in Biostatistics from Harvard University, and a PhD in Biostatistics from the University of Pittsburgh. Beth is the director of the Carlow Honors Program and the interim Associate Dean of Student Success and Engagement for the College of Arts and Sciences. Her primary teaching responsibilities are in the field of Statistics. She currently teaches Basic Applied Statistics courses to Carlow undergraduates and serves as a statistical consultant to Carlow’s FNP and DNP programs. Beth’s research interests include cancer drug development and cancer chemotherapy exposure. She is the co-author of over fifty clinical cancer articles and abstracts. Before coming to Carlow, Beth worked as a Biostatistician for the University of Pittsburgh Cancer Institute.

Education

  • PhD – Biostatistics, University of Pittsburgh, Pittsburgh, PA (2015)
  • MS – Biostatistics, Harvard University, Boston, MA (1999)
  • BS – Summa Cum Laude in Statistics, University of Pittsburgh, Pittsburgh, PA (1997)

Research

Interests: Cancer Drug Development; Cancer Chemotherapy Exposure

  • Statistical consultant, work with more than 80 DNP students at Carlow University on the development and analyses of DNP student projects (2010 – Present)
  • Statistical consultant for the Dionne’s Project, worked with investigators to develop and implement statistical analyses on Bystander Awareness studies (2009 – 2013)

Publications

  • Abigail Hebb, DNP, RN, NE-BC, CMSRN, Michael Kistler, PhD, Elizabeth George, PhD, RN, Beth Zamboni PhD. Satisfaction and Technology Acceptance of Staff Utilizing Continuous Video Monitoring in Comparison to Sitters. Accepted to The Journal of Nursing Administration. (February 2021) 
  • Hwang JJ, Zamboni WC, Malik S, Hansen N, Strychor S, Zamboni BA, Sidone BJ*, Marshall JL. Phase I and pharmacokinetic study of weekly docetaxel and oxaliplatin in patients with advanced solid tumors. Submitted to Clinical Cancer Res. (September 2020)
  • Salch SA, Zamboni WC, Zamboni BA, Eckel SF. Patterns and characteristics associated with the surface contamination of hazardous drugs in hospital pharmacies. Am J Health Syst Pharm. (April 17, 2019)
  • Rodgers, J., Slota, P., & Zamboni, B. Exertional Heat Illness Among Secondary School Athletes: Statewide Policy Implications. The Journal of School Nursing, 34(2), 156–164. (2018) 
  • Giovinazzo H, Kumar P, Sheikh A, Brooks KM, Ivanovic M, Walsh M, Caron WP, Kowalsky RJ, Song G, Whitlow A, Clarke-Pearson DL, Brewster WR, Van Le L, Zamboni BA, Bae-Jump V, Gehrig PA, Zamboni WC. Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer. Cancer Chemother Pharmacol. (2016)
  • Zamboni BA, Anderson SJ. TWISTED Survival – Identifying Surrogate Endpoints for Mortality Using QTWIST and Conditional Disease Free Survival. D-Scholarship.Pitt.edu (2015) 
  • Wu, H., Infante, J. R., Keedy, V. L., Jones, S. F., Chan, E., Bendell, J. C., Lee, W., Kirschbrown, W. P., Zamboni, B. A., Ikeda, S., Kodaira, H., Rothenberg, M. L., Burris, H. A., Zamboni, W. C. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. International journal of nanomedicine. (2015) 
  • Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, Ramanathan RK, Zamboni WC. Meta-analysis of study design issues and pharmacokinetic variability of liposomal and non-liposomal anticancer agents in patients. Nanomed. (2014) 
  • Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. Eur J Clin Pharmacol. (2013)
  • Caron WP, Morgan KP, Zamboni BA, Zamboni WC. A review of study designs and outcomes of phase I clinical studies of nanoparticle agents compared with small molecule anticancer agents. Clinical Cancer Res. (2013) 
  • Caron WP, Lay JC, Fong AM, La-Beck NM, Kumar P, Newman SE, Zamboni BA, Crona DJ, Clarke-Pearson DL, Brewster WR, Le LV, Bae-Jump V, Gehrig PA, Zamboni WC. Translational studies of phenotypic probes of the mononuclear phagocyte system and nanosomal pharmacology. J of Pharmacol Exp Ther. (2013) 
  • Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, Habibi S, Zamboni BA, Muller M, Brunner M, Sharpless NE, Zamboni WC.  Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. The Oncologist. (2012) 
  • Wu H, Ramanathan RK, Zamboni BA, Strychor S, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Bang YJ, Zamboni WC. Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients. International Journal of Nanomedicine. (2012)
  • Walsh MD, Hanna SK, Sen JM, Rawal S, Benson JD, Cabral CB, Yurkovetskiy A, Lowinger TB, Zamboni BA, Zamboni WC. Pharmacokinetics of XMT-1001, a novel polymeric prodrug of camptothecin, in mice bearing HT-29 human colon carcinoma xenografts. Clinical Cancer Res. (2012) 
  • La-Beck NM, Zamboni BA, Gabizon A, Sidone BJ, Edwards RP, Tzemach D, Schmeeda H, Sapir R, Amantea M, Zamboni WC. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.  Cancer Chemotherapy Pharmacol. (2012) 
  • Zamboni WC, Combest AJ, DeLoia j, Edwards R, Bridges A, Zamboni BA, Walko CW, Yu AYC, Krivak T, Kelley J. Pharmacologic and phenotypic study of docetaxel in patients with ovarian cancer or primary peritoneal cancer. Cancer Chemotherapy and Pharmacology, Online First. (March 25, 2011) 
  • Wu H, Ramanathan RK, Strychor S, Zamboni BA, Ramalingam S, Edwards RP, Friedland DM, Stoller RG, Belani CP, Maruca LJ, Kim JK, Bang YJ, Lee HY, Zamboni WC. Population pharmacokinetics of PEGylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Journal of Clinical Pharmacokinetics. (January 13, 2011)
  • Zamboni WC, Maruca L, Strychor S, Zamboni BA, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK.  Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with solid tumors. Clinical Pharmacol Ther. (2010) 
  • Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Engber C, Basse PH. Tumor disposition of pegylated liposomal CKD-602 (S-CKD602) and the reticuloendothelial system in preclinical tumor models. J of Liposome Research. (2010) 
  • Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, Thomas CR, O’Connell MJ, Wolmark N, Wang SJ. Conditional Survival for Patients with Colon Cancer: An Analysis of NSABP Trials C-03 through C-07.  Journal of Clinical Oncology. (2010) 
  • Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK. Phase I and pharmacokinetic study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. Clin Cancer Res. (2009) 
  • Zamboni WC, Strychor S, Maruca L, Ramalingam S, Zamboni BA, Wu H, Friedland DM, Edwards RP, Stoller RG, Belani CP, Ramanathan RK. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clin Pharmacol Ther. (2009) 
  • Zamboni WC, Ramalingam S, Friedland DM, Edwards RP, Stoller RG, Strychor S, Maruca L, Zamboni BA, Belani CP, Ramanathan RK.  Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies.  Clin. Cancer Res. (2009)  
  • Zamboni WC, Jung LL, Strychor S, Joseph E, Zamboni BA, Fetterman SA, Sidone BJ, Burke TG, Curran DP, Eiseman JL. Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice. Invest New Drugs. (2008) 
  • Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engber C, Eiseman JL. Plasma, Tumor, and Tissue Disposition of STEALTH Liposomal CKD-602 (S-CKD602) and Non-Liposomal CKD-602 in Mice Bearing A375 Human Melanoma Xenografts. Clin. Cancer Res. (2007) 
  • Xi S, Dyer KF, Kimak M, Zhang Q, Gooding WE,Chaillet JF, Chai RL, Ferrell RE, Zamboni B, Hunt J, Rubin-Grandis J. Decreased STAT1 Expression by Promoter Methylation in Squamous Cell Carcinogenesis. J Natl Cancer Inst. (2006) 
  • Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM. Transgenic Mice Overexpressing Hepatocyte Growth Factor in the Airways Show Increased Susceptibility to Lung Cancer.  Carcinogenesis. (2006) 
  • Fakih MG, Creaven PJ, Ramnath N, Trump D, Javle M, Strychor S, Repinski TV, Zamboni BA, Schwarz JK, French RA, Zamboni WC. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res. (2005)
  • Rubin-Grandis J, Gooding WE, Zamboni BA, Wagener MM, Drenning SD. Miller L, Doyle KJ, Mackinnon SE, Wagner RL. The Gender Gap in Surgical Subspecialty: Analysis of Career and Lifestyle Factors. Arch Otolaryngol Head Neck Surg. (2004) 
  • Ramalingam S, Belani CP, Day RS, Zamboni, BA, Jacobs SA, Jett JR. Phase II Study of Topotecan and Paclitaxel for Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer. Annals of Oncology. (2004) 
    © Copyright 2024 Carlow University. All rights reserved.
    Carlow University prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to the Title IX Coordinator, Jackie smith at jmsmith@carlow.edu or 412-578-6050.